Brookfield Withdraws €6.45 Billion Bid for Spanish Pharma Giant Grifols

The Canadian fund ended months of negotiations after failing to agree on a valuation with Grifols, whose shares fell following the announcement.

Brookfield Asset Management has abandoned its €6.45 billion offer to take Spanish pharmaceutical firm Grifols private due to disagreements over the company’s valuation.
The bid, supported by the Grifols family, proposed a non-binding price of €10.50 per share, which the Grifols board rejected as undervaluing the company’s long-term potential.
Grifols shares dropped by nearly 9% on Wednesday following the announcement of Brookfield's withdrawal.
Grifols has faced scrutiny this year after short-seller Gotham City Research accused the company of manipulating financial figures, allegations the company has denied.
The Barcelona-based firm, a global leader in plasma-derived medicines, remains focused on improving its long-term value while navigating investor pressure and governance changes.